Complete financial analysis of Imugene Limited (IUGNF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Imugene Limited, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PPG Industries, Inc. (PPG) Income Statement Analysis – Financial Results
- KOSÉ Corporation (KSRYY) Income Statement Analysis – Financial Results
- Ascension Capital Limited (ACE.NZ) Income Statement Analysis – Financial Results
- Aeries Technology, Inc (AERTW) Income Statement Analysis – Financial Results
- Royal Bank of Canada (0QKU.L) Income Statement Analysis – Financial Results
Imugene Limited (IUGNF)
About Imugene Limited
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 11.78M | 12.97M | 7.23M | 4.13M | 4.13M | 1.84M | 1.16M | 1.56M | 638.68K | 538.31K | 207.22K | 235.91K | 2.23M | 0.00 | 0.00 | 0.00 | 374.56K | 0.00 | 0.00 | 0.00 | 19.00 | 1.29M | 114.24K | 0.00 | 0.00 | 0.00 | 3.86M | 278.00K | 188.00K | 0.00 | 0.00 |
| Cost of Revenue | 5.84M | 2.20M | 2.41M | 1.96M | 82.50K | 63.26K | 2.68K | 1.74K | 1.16K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 175.00K | 107.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -5.84M | 9.57M | 10.56M | 5.27M | 4.05M | 4.06M | 1.84M | 1.16M | 1.56M | 638.68K | 538.31K | 207.22K | 235.91K | 2.23M | 0.00 | 0.00 | 0.00 | 374.56K | 0.00 | 0.00 | 0.00 | 19.00 | 1.12M | 7.04K | 0.00 | 0.00 | 0.00 | 3.86M | 278.00K | 188.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 81.29% | 81.44% | 72.86% | 98.00% | 98.47% | 99.85% | 99.85% | 99.93% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 86.45% | 6.17% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 86.89M | 30.86M | 36.61M | 15.36M | 9.36M | 7.61M | 4.15M | 2.47M | 2.70M | 1.67M | 469.46K | 603.32K | 285.44K | 491.69K | 522.34K | 466.48K | 1.32M | 1.08M | 845.02K | 810.38K | 885.79K | 943.96K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 17.77M | 12.10M | 9.44M | 4.29M | 3.81M | 1.21M | 894.06K | 1.09M | 875.05K | 762.51K | 1.08M | 572.11K | 1.05M | 976.87K | 1.69M | 853.93K | 1.14M | 568.12K | 972.27K | 784.11K | 548.16K | 0.00 | 1.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 506.52K | 334.90K | 154.85K | 282.34K | 426.25K | 0.00 | 318.69K | 479.26K | 340.97K | 42.01K | 51.31K | 0.00 | 0.00 | 0.00 | 197.79K | 38.21K | 0.00 | 0.00 | 247.50K | 249.78K | 0.00 | 0.00 | 562.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 48.21M | 18.22M | 12.43M | 9.59M | 4.58M | 4.23M | 1.21M | 894.06K | 1.09M | 875.05K | 804.53K | 1.14M | 572.11K | 1.05M | 976.87K | 1.69M | 853.93K | 1.14M | 568.12K | 1.22M | 1.03M | 548.16K | 0.00 | 1.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 11.53M | 12.84M | 7.20M | 4.07M | 4.21M | 1.75M | 1.14M | 1.50M | 679.52K | 883.99K | 156.66K | 114.50K | -171.66K | 312.12K | 3.17M | 340.63K | 372.99K | 169.77K | 254.77K | 43.00K | 509.06K | -466.00K | -1.30M | -4.40M | -4.90M | -4.52M | -3.86M | 593.00K | 747.00K | 766.00K | 262.00K |
| Operating Expenses | 135.09M | 49.09M | 50.67M | 25.67M | 14.88M | 12.39M | 5.78M | 3.69M | 4.27M | 2.88M | 1.34M | 1.74M | 1.40M | 1.89M | 2.12M | 2.76M | 2.56M | 3.04M | 3.15M | 2.51M | 2.44M | 2.43M | 328.00K | 2.58M | -4.40M | -4.90M | -4.52M | 1.39M | 871.00K | 935.00K | 766.00K | 262.00K |
| Cost & Expenses | 140.93M | 51.29M | 50.67M | 25.67M | 14.88M | 12.39M | 5.78M | 3.69M | 4.27M | 2.88M | 1.34M | 1.74M | 1.40M | 1.89M | 2.12M | 2.76M | 2.56M | 3.04M | 3.15M | 2.51M | 2.44M | 2.43M | 503.00K | 2.69M | -4.40M | -4.90M | -4.52M | 1.39M | 871.00K | 935.00K | 766.00K | 262.00K |
| Interest Income | 4.52M | 1.88M | 192.25K | 126.57K | 302.19K | 414.89K | 94.33K | 35.43K | 39.40K | 38.36K | 27.10K | 23.21K | 8.68K | 10.25K | 44.02K | 76.61K | 67.21K | 101.69K | 196.56K | 134.73K | 80.60K | 29.47K | 12.00K | 8.32K | 0.00 | 0.00 | 0.00 | 59.00K | 14.00K | 133.00K | 79.00K | 0.00 |
| Interest Expense | 478.36K | 27.45K | 106.74K | 111.03K | 5.03K | 6.11K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 180.95K | 18.00K | 27.00K | 28.00K | 68.00K | 97.00K | 0.00 | 33.00K | 23.00K |
| Depreciation & Amortization | 5.84M | 2.20M | 2.41M | 1.96M | 82.50K | 63.26K | 2.68K | 1.74K | 1.16K | 2.25M | 676.00 | 676.00 | 172.11K | 343.15K | 343.01K | 343.18K | 343.85K | 345.71K | 346.65K | 347.67K | 348.59K | 132.23K | 328.00K | 439.64K | 0.00 | 0.00 | 0.00 | 572.00K | 581.00K | 491.00K | 328.00K | 163.00K |
| EBITDA | -135.09M | -37.26M | -37.45M | -18.24M | -10.42M | -7.71M | -5.78M | -3.68M | -4.27M | -194.89K | -796.82K | -1.74M | -995.33K | 682.09K | -1.78M | -2.41M | -2.22M | -2.69M | -2.81M | -2.17M | -1.62M | -2.30M | -770.00K | -3.42M | -4.40M | -4.90M | -4.52M | -2.11M | -4.15M | -1.51M | -871.00K | -305.00K |
| EBITDA Ratio | 0.00% | -416.80% | -288.78% | -252.23% | -252.08% | -186.70% | -313.88% | -316.56% | -272.82% | -408.73% | 66.03% | -839.09% | 463.67% | 30.63% | 0.00% | 0.00% | 0.00% | -619.88% | 0.00% | 0.00% | 0.00% | -12,085,773.68% | -59.61% | -2,994.51% | 0.00% | 0.00% | 0.00% | -54.78% | -1,491.73% | -804.79% | 0.00% | 0.00% |
| Operating Income | -140.93M | -51.29M | -37.66M | -18.34M | -10.50M | -7.77M | -5.78M | -3.69M | -4.27M | -2.61M | 355.45K | -1.74M | 921.74K | 338.94K | -2.12M | -2.76M | -2.56M | -2.67M | -3.15M | -2.51M | -1.97M | -2.43M | -1.10M | -3.86M | -4.40M | -4.90M | -4.52M | -2.69M | -4.73M | -2.00M | -1.20M | -468.00K |
| Operating Income Ratio | 0.00% | -435.51% | -290.35% | -253.67% | -254.07% | -188.23% | -314.03% | -316.71% | -272.89% | -408.73% | 66.03% | -839.41% | 390.71% | 15.22% | 0.00% | 0.00% | 0.00% | -712.18% | 0.00% | 0.00% | 0.00% | -12,781,710.53% | -85.00% | -3,379.35% | 0.00% | 0.00% | 0.00% | -69.60% | -1,700.72% | -1,065.96% | 0.00% | 0.00% |
| Total Other Income/Expenses | -13.37M | 1.60M | -165.91K | -20.76K | 237.35K | 486.39K | 3.50K | 14.28K | -26.10K | -194.89K | -1.32M | -27.35K | -1.97M | -159.40K | 358.00K | 3.01M | 410.55K | 106.26K | 712.98K | 396.03K | -819.82K | 384.41K | -1.57M | -180.95K | -18.41K | -27.00K | -28.00K | -6.04M | -3.65M | -766.00K | 295.00K | 140.00K |
| Income Before Tax | -154.30M | -49.66M | -37.87M | -18.46M | -10.51M | -7.78M | -3.93M | -2.51M | -2.73M | -2.44M | -2.12M | -1.56M | -3.13M | 179.54K | -1.77M | 252.50K | -2.15M | -2.56M | -2.44M | -2.12M | -2.79M | -2.04M | -782.00K | -4.04M | -4.42M | -4.93M | -4.55M | -2.18M | -4.24M | -1.51M | -904.00K | -328.00K |
| Income Before Tax Ratio | 0.00% | -421.62% | -291.98% | -255.21% | -254.19% | -188.39% | -213.69% | -215.33% | -174.56% | -382.16% | -393.07% | -752.61% | -1,328.22% | 8.06% | 0.00% | 0.00% | 0.00% | -683.81% | 0.00% | 0.00% | 0.00% | -10,758,515.79% | -60.54% | -3,537.75% | 0.00% | 0.00% | 0.00% | -56.54% | -1,526.62% | -804.79% | 0.00% | 0.00% |
| Income Tax Expense | -4.62M | -11.74M | 12.94M | 7.31M | 4.08M | 4.21M | -97.01K | -37.17K | -39.40K | -2.01M | 1.66M | -23.21K | 2.08M | -236.00K | -230.00K | -397.79K | -238.74K | -257.05K | -252.06K | -2.12M | -2.79M | -2.04M | -782.00K | -4.04M | -4.42M | -4.93M | -4.55M | -2.18M | -4.24M | -1.51M | -904.00K | -328.00K |
| Net Income | -149.68M | -37.91M | -37.87M | -18.46M | -10.51M | -7.78M | -3.93M | -2.51M | -2.73M | -2.44M | -2.12M | -1.56M | -3.13M | 415.54K | -1.54M | 650.29K | -1.91M | -2.30M | -2.19M | -1.79M | -2.12M | 699.06K | -782.00K | -4.04M | -4.42M | -4.93M | -4.55M | -2.18M | -4.24M | -2.14M | -875.00K | 243.00K |
| Net Income Ratio | 0.00% | -321.92% | -291.98% | -255.21% | -254.19% | -188.39% | -213.69% | -215.33% | -174.56% | -382.16% | -393.07% | -752.61% | -1,328.22% | 18.66% | 0.00% | 0.00% | 0.00% | -615.19% | 0.00% | 0.00% | 0.00% | 3,679,200.00% | -60.54% | -3,537.75% | 0.00% | 0.00% | 0.00% | -56.54% | -1,526.62% | -1,135.64% | 0.00% | 0.00% |
| EPS | -0.02 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 | -0.01 | 0.00 | -0.01 | -0.02 | -0.02 | -0.01 | -0.02 | -0.02 | -0.04 | -1.60 | -1.84 | -2.27 | -2.35 | -1.37 | -2.92 | -1.53 | -0.83 | 0.34 |
| EPS Diluted | -0.02 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 | -0.01 | 0.00 | -0.01 | -0.02 | -0.02 | -0.01 | -0.02 | -0.02 | -0.04 | -1.60 | -1.84 | -2.27 | -2.35 | -1.37 | -2.92 | -1.53 | -0.83 | 0.34 |
| Weighted Avg Shares Out | 7.09B | 6.28B | 5.64B | 4.66B | 4.07B | 3.58B | 2.64B | 2.09B | 1.33B | 1.19B | 695.41M | 327.84M | 144.93M | 144.93M | 144.93M | 144.93M | 137.66M | 132.17M | 132.17M | 121.58M | 109.03M | 71.24M | 21.14M | 2.52M | 2.40M | 2.17M | 1.94M | 1.59M | 1.45M | 1.40M | 1.05M | 292.05K |
| Weighted Avg Shares Out (Dil) | 7.09B | 6.28B | 5.64B | 4.66B | 4.07B | 3.58B | 2.64B | 2.09B | 1.33B | 1.19B | 695.41M | 327.84M | 144.93M | 144.93M | 144.93M | 164.04M | 137.66M | 132.17M | 132.17M | 121.58M | 109.03M | 71.24M | 21.14M | 2.52M | 2.40M | 2.17M | 1.94M | 1.59M | 1.45M | 1.40M | 1.05M | 292.05K |
Bile Tract Cancer expansion study opens following clearance of Imugene's MAST trial high dose cohort
The expansion trial is expected to enrol 10 patients with bile tract cancers (cholangiocarcinoma) Interim results from the MAST trial have demonstrated positive responses in gastrointestinal cancers, particularly in cholangiocarcinoma where one patient treated with CF33-hNIS (VAXINIA) achieved a complete...
Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024
Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients. Encouraging VAXINIA efficacy, including a complete response (CR) and two partial responses (PRs), has warranted cohort expansions in biliary tract cancer...
Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts
Five clinical trials across three prioritized immuno-oncology platforms with encouraging safety and efficacy signals Encouraging early results from the VAXINIA (CF33) oncolytic virus trial, including one complete response in a patient with cholangiocarcinoma (bile tract cancer) and two partial responses...
Imugene's CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers Symposium
SYDNEY, AUSTRALIA / ACCESSWIRE / January 18, 2024 / Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce further details from its poster presentation at the ASCO Gastrointestinal Cancers Symposium (ASCO-GI) currently being conducted in San Francisco....
NeoImmuneTech and Imugene enter into strategic research collaboration to improve cancer treatments
The collaboration will evaluate the ability of NeoImmuneTech's immune cell amplifier NT-I7 to increase the number of azer-cel allogeneic CAR T cells per batch during manufacturing. The combination potential of azer-cel and NT-I7 to increase the number and cancer-fighting properties...
Imugene appoints experienced life sciences CFO in newly created in-house role
Imugene Ltd (ASX:IMU, OTC:IUGNF) (Imugene Ltd (ASX:IMU, OTC:IUGNF), Imugene Ltd (ASX:IMU, OTC:IUGNF)) has signed up a chief financial officer (CFO) in a newly created in-house role which will see Mike Tonroe lead the company's finance function. Tonroe has extensive experience as...
Imugene Announces Clinical Trial Collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to Evaluate HER-Vaxx in Combination with Pembrolizumab for Treatment of Gastric Cancer
SYDNEY, Australia, March 14, 2022 (GLOBE NEWSWIRE) -- Imugene (ASX: IMU) today announced a new clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to evaluate the safety and efficacy of Imugene's...
Imugene tagged a "buy" by Roth Capital Partners after securing Roche clinical supply deal and patents in Europe and Japan
Imugene Ltd (ASX:IMU, OTC:IUGNF)'s recent clinical and patent activities have drawn the attention of Roth Capital Partners, which has placed a “buy” recommendation on the clinical stage cancer-focused biotech. The company has secured a clinical supply deal for its upcoming...
Imugene bolsters executive management team with Dr Steven Cha appointed chief medical officer
Imugene Ltd (ASX:IMU, OTC:IUGNF) has appointed Dr Steven Cha as its chief medical officer (CMO) and a member of its executive management team. Dr Cha will lead the company's global clinical development efforts and medical affairs at a pivotal time...
Imugene secures Japanese grant notice for Oncolytic Virotherapy CF33 Patent
Imugene Ltd (ASX:IMU, OTC:IUGNF) has received a notice of grant from the Japanese Patent Office for Patent Application number 2019-507161 which protects its oncolytic virotherapy CF33, including VAXINIA (CF33-hNIS) and CHECKVacc (CF33-hNIS-antiPDL1). The Japanese patent grants exposure to a major...
Source: https://incomestatements.info
Category: Stock Reports